Revance Therapeutics Inc (RVNC) Expected to Post Quarterly Sales of $490,000.00

Analysts expect Revance Therapeutics Inc (NASDAQ:RVNC) to post $490,000.00 in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Revance Therapeutics’ earnings, with estimates ranging from $100,000.00 to $700,000.00. Revance Therapeutics reported sales of $80,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 512.5%. The firm is expected to issue its next quarterly earnings report after the market closes on Thursday, November 1st.

On average, analysts expect that Revance Therapeutics will report full year sales of $1.89 million for the current financial year, with estimates ranging from $1.10 million to $2.28 million. For the next year, analysts forecast that the business will post sales of $2.03 million, with estimates ranging from $500,000.00 to $2.88 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Revance Therapeutics.

Revance Therapeutics (NASDAQ:RVNC) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.02). The business had revenue of $0.69 million for the quarter, compared to the consensus estimate of $0.93 million. Revance Therapeutics had a negative net margin of 13,690.62% and a negative return on equity of 63.30%.

A number of equities analysts recently commented on RVNC shares. BidaskClub upgraded Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 14th. ValuEngine upgraded Revance Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd. Zacks Investment Research downgraded Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, October 4th. Cantor Fitzgerald set a $50.00 target price on Revance Therapeutics and gave the company a “buy” rating in a report on Thursday, August 2nd. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Revance Therapeutics in a report on Monday, September 17th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $47.10.

Shares of Revance Therapeutics stock opened at $23.95 on Friday. The company has a market cap of $914.95 million, a P/E ratio of -6.12 and a beta of 1.29. Revance Therapeutics has a 52 week low of $22.25 and a 52 week high of $37.45.

A number of hedge funds have recently modified their holdings of the stock. Nottingham Advisors Inc. grew its stake in Revance Therapeutics by 17.7% in the second quarter. Nottingham Advisors Inc. now owns 13,312 shares of the biopharmaceutical company’s stock worth $365,000 after purchasing an additional 2,000 shares during the period. Voya Investment Management LLC grew its stake in Revance Therapeutics by 19.6% in the second quarter. Voya Investment Management LLC now owns 12,433 shares of the biopharmaceutical company’s stock worth $341,000 after purchasing an additional 2,041 shares during the period. Metropolitan Life Insurance Co. NY grew its stake in Revance Therapeutics by 25.8% in the second quarter. Metropolitan Life Insurance Co. NY now owns 10,875 shares of the biopharmaceutical company’s stock worth $299,000 after purchasing an additional 2,232 shares during the period. The Manufacturers Life Insurance Company grew its stake in Revance Therapeutics by 12.5% in the first quarter. The Manufacturers Life Insurance Company now owns 20,446 shares of the biopharmaceutical company’s stock worth $630,000 after purchasing an additional 2,274 shares during the period. Finally, Cubist Systematic Strategies LLC grew its stake in Revance Therapeutics by 43.2% in the second quarter. Cubist Systematic Strategies LLC now owns 8,795 shares of the biopharmaceutical company’s stock worth $241,000 after purchasing an additional 2,654 shares during the period. 94.30% of the stock is currently owned by institutional investors.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.

Recommended Story: How to calculate the intrinsic value of a stock

Get a free copy of the Zacks research report on Revance Therapeutics (RVNC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply